ID   AADAT_HUMAN             Reviewed;         425 AA.
AC   Q8N5Z0; B3KP84; Q9UL02;
DT   13-APR-2004, integrated into UniProtKB/Swiss-Prot.
DT   13-APR-2004, sequence version 2.
DT   12-APR-2017, entry version 139.
DE   RecName: Full=Kynurenine/alpha-aminoadipate aminotransferase, mitochondrial;
DE            Short=KAT/AadAT;
DE   AltName: Full=2-aminoadipate aminotransferase;
DE   AltName: Full=2-aminoadipate transaminase;
DE            EC=2.6.1.39;
DE   AltName: Full=Alpha-aminoadipate aminotransferase;
DE            Short=AadAT;
DE   AltName: Full=Kynurenine aminotransferase II;
DE   AltName: Full=Kynurenine--oxoglutarate aminotransferase II;
DE   AltName: Full=Kynurenine--oxoglutarate transaminase 2;
DE            EC=2.6.1.7;
DE   AltName: Full=Kynurenine--oxoglutarate transaminase II;
DE   Flags: Precursor;
GN   Name=AADAT; Synonyms=KAT2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RA   Gatti S., Breton J., Mostardini M., Mosca M., Tarroni P., Schwarcz R.,
RA   Speciale C., Okuno E., Toma S., Benatti L.;
RT   "Cloning of human L-kynurenine/alpha-aminoadipate aminotransferase
RT   cDNA from brain tissue.";
RL   Submitted (OCT-1998) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), CATALYTIC ACTIVITY, AND
RP   COFACTOR.
RX   PubMed=12126930; DOI=10.1016/S1096-7192(02)00037-9;
RA   Goh D.L.M., Patel A., Thomas G.H., Salomons G.S., Schor D.S.M.,
RA   Jakobs C., Geraghty M.T.;
RT   "Characterization of the human gene encoding alpha-aminoadipate
RT   aminotransferase (AADAT).";
RL   Mol. Genet. Metab. 76:172-180(2002).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [6]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) IN COMPLEX WITH 2-OXOGLUTARATE,
RP   CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, ENZYME REGULATION,
RP   SUBUNIT, AND FUNCTION.
RX   PubMed=18620547; DOI=10.1042/BSR20080085;
RA   Han Q., Cai T., Tagle D.A., Robinson H., Li J.;
RT   "Substrate specificity and structure of human aminoadipate
RT   aminotransferase/kynurenine aminotransferase II.";
RL   Biosci. Rep. 28:205-215(2008).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) IN COMPLEX WITH PYRIDOXAL
RP   PHOSPHATE AND KYRUNENINE, CATALYTIC ACTIVITY, COFACTOR, AND SUBUNIT.
RX   PubMed=18056995; DOI=10.1074/jbc.M708358200;
RA   Han Q., Robinson H., Li J.;
RT   "Crystal structure of human kynurenine aminotransferase II.";
RL   J. Biol. Chem. 283:3567-3573(2008).
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) IN COMPLEX WITH PYRIDOXAL
RP   PHOSPHATE, SUBUNIT, AND COFACTOR.
RX   PubMed=18056996; DOI=10.1074/jbc.M707925200;
RA   Rossi F., Garavaglia S., Montalbano V., Walsh M.A., Rizzi M.;
RT   "Crystal structure of human kynurenine aminotransferase II, a drug
RT   target for the treatment of schizophrenia.";
RL   J. Biol. Chem. 283:3559-3566(2008).
CC   -!- FUNCTION: Transaminase with broad substrate specificity. Has
CC       transaminase activity towards aminoadipate, kynurenine, methionine
CC       and glutamate. Shows activity also towards tryptophan, aspartate
CC       and hydroxykynurenine. Accepts a variety of oxo-acids as amino-
CC       group acceptors, with a preference for 2-oxoglutarate, 2-
CC       oxocaproic acid, phenylpyruvate and alpha-oxo-gamma-methiol
CC       butyric acid. Can also use glyoxylate as amino-group acceptor (in
CC       vitro). {ECO:0000269|PubMed:18620547}.
CC   -!- CATALYTIC ACTIVITY: L-kynurenine + 2-oxoglutarate = 4-(2-
CC       aminophenyl)-2,4-dioxobutanoate + L-glutamate.
CC   -!- CATALYTIC ACTIVITY: L-2-aminoadipate + 2-oxoglutarate = 2-
CC       oxoadipate + L-glutamate.
CC   -!- COFACTOR:
CC       Name=pyridoxal 5'-phosphate; Xref=ChEBI:CHEBI:597326;
CC         Evidence={ECO:0000269|PubMed:12126930,
CC         ECO:0000269|PubMed:18056995, ECO:0000269|PubMed:18056996};
CC   -!- ENZYME REGULATION: Kynurenine transaminase activity is
CC       competitively inhibited by aminoadipate, asparagine, glutamate,
CC       histidine, cysteine, lysine, 3-hydroxy-kynurenine and
CC       phenylalanine. {ECO:0000269|PubMed:18620547}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=0.9 mM for aminoadipate {ECO:0000269|PubMed:18620547};
CC         KM=4.7 mM for kynurenine {ECO:0000269|PubMed:18620547};
CC         KM=1.7 mM for methionine {ECO:0000269|PubMed:18620547};
CC         KM=1.6 mM for glutamate {ECO:0000269|PubMed:18620547};
CC         KM=1.8 mM for tyrosine {ECO:0000269|PubMed:18620547};
CC         KM=1.2 mM for 2-oxoglutarate {ECO:0000269|PubMed:18620547};
CC         KM=1.5 mM for 2-oxocaproic acid {ECO:0000269|PubMed:18620547};
CC         KM=1.8 mM for phenylpyruvate {ECO:0000269|PubMed:18620547};
CC         KM=1.4 mM for ino-3-pyruvate {ECO:0000269|PubMed:18620547};
CC       pH dependence:
CC         Optimum pH is 7-9. {ECO:0000269|PubMed:18620547};
CC       Temperature dependence:
CC         Optimum temperature is 50 degrees Celsius.
CC         {ECO:0000269|PubMed:18620547};
CC   -!- PATHWAY: Amino-acid degradation; L-lysine degradation via
CC       saccharopine pathway; glutaryl-CoA from L-lysine: step 4/6.
CC   -!- SUBUNIT: Homodimer. {ECO:0000269|PubMed:18056995,
CC       ECO:0000269|PubMed:18056996, ECO:0000269|PubMed:18620547}.
CC   -!- SUBCELLULAR LOCATION: Mitochondrion {ECO:0000305}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q8N5Z0-1; Sequence=Displayed;
CC         Note=May be due to a competing donor splice site.;
CC       Name=2;
CC         IsoId=Q8N5Z0-2; Sequence=VSP_009874;
CC   -!- TISSUE SPECIFICITY: Higher expression in the liver. Also found in
CC       heart, brain, kidney, pancreas, prostate, testis and ovary.
CC   -!- SIMILARITY: Belongs to the class-I pyridoxal-phosphate-dependent
CC       aminotransferase family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF097994; AAF04623.1; -; mRNA.
DR   EMBL; AF481738; AAM09683.1; -; mRNA.
DR   EMBL; AK055952; BAG51596.1; -; mRNA.
DR   EMBL; BC031068; AAH31068.1; -; mRNA.
DR   CCDS; CCDS3814.1; -. [Q8N5Z0-1]
DR   CCDS; CCDS75209.1; -. [Q8N5Z0-2]
DR   RefSeq; NP_001273611.1; NM_001286682.1. [Q8N5Z0-2]
DR   RefSeq; NP_001273612.1; NM_001286683.1. [Q8N5Z0-1]
DR   RefSeq; NP_057312.1; NM_016228.3. [Q8N5Z0-1]
DR   RefSeq; NP_872603.1; NM_182662.1. [Q8N5Z0-1]
DR   UniGene; Hs.529735; -.
DR   PDB; 2QLR; X-ray; 2.30 A; A/B/C/D=1-425.
DR   PDB; 2R2N; X-ray; 1.95 A; A/B/C/D=1-425.
DR   PDB; 2VGZ; X-ray; 2.30 A; A/B=2-425.
DR   PDB; 2XH1; X-ray; 2.10 A; A/B=1-425.
DR   PDB; 3DC1; X-ray; 2.50 A; A/B/C/D=1-425.
DR   PDB; 3UE8; X-ray; 3.22 A; A/B=1-425.
DR   PDB; 4GDY; X-ray; 2.89 A; A/B=1-425.
DR   PDB; 4GE4; X-ray; 2.41 A; A/B=1-425.
DR   PDB; 4GE7; X-ray; 2.10 A; A/B=1-425.
DR   PDB; 4GE9; X-ray; 2.43 A; A/B/C/D=1-425.
DR   PDB; 4GEB; X-ray; 2.15 A; A/B=1-425.
DR   PDB; 5EFS; X-ray; 1.83 A; A=1-425.
DR   PDB; 5EUN; X-ray; 1.82 A; A=1-425.
DR   PDB; 5TF5; X-ray; 1.81 A; A/B=1-425.
DR   PDBsum; 2QLR; -.
DR   PDBsum; 2R2N; -.
DR   PDBsum; 2VGZ; -.
DR   PDBsum; 2XH1; -.
DR   PDBsum; 3DC1; -.
DR   PDBsum; 3UE8; -.
DR   PDBsum; 4GDY; -.
DR   PDBsum; 4GE4; -.
DR   PDBsum; 4GE7; -.
DR   PDBsum; 4GE9; -.
DR   PDBsum; 4GEB; -.
DR   PDBsum; 5EFS; -.
DR   PDBsum; 5EUN; -.
DR   PDBsum; 5TF5; -.
DR   ProteinModelPortal; Q8N5Z0; -.
DR   SMR; Q8N5Z0; -.
DR   BioGrid; 119346; 1.
DR   STRING; 9606.ENSP00000226840; -.
DR   BindingDB; Q8N5Z0; -.
DR   ChEMBL; CHEMBL2046259; -.
DR   DrugBank; DB00142; L-Glutamic Acid.
DR   DrugBank; DB00114; Pyridoxal Phosphate.
DR   iPTMnet; Q8N5Z0; -.
DR   PhosphoSitePlus; Q8N5Z0; -.
DR   BioMuta; AADAT; -.
DR   DMDM; 46395904; -.
DR   EPD; Q8N5Z0; -.
DR   MaxQB; Q8N5Z0; -.
DR   PaxDb; Q8N5Z0; -.
DR   PeptideAtlas; Q8N5Z0; -.
DR   PRIDE; Q8N5Z0; -.
DR   DNASU; 51166; -.
DR   Ensembl; ENST00000337664; ENSP00000336808; ENSG00000109576. [Q8N5Z0-1]
DR   Ensembl; ENST00000353187; ENSP00000226840; ENSG00000109576. [Q8N5Z0-1]
DR   Ensembl; ENST00000509167; ENSP00000423190; ENSG00000109576. [Q8N5Z0-2]
DR   Ensembl; ENST00000515480; ENSP00000423341; ENSG00000109576. [Q8N5Z0-1]
DR   GeneID; 51166; -.
DR   KEGG; hsa:51166; -.
DR   UCSC; uc003isr.4; human. [Q8N5Z0-1]
DR   CTD; 51166; -.
DR   GeneCards; AADAT; -.
DR   HGNC; HGNC:17929; AADAT.
DR   HPA; HPA037502; -.
DR   MIM; 611754; gene.
DR   neXtProt; NX_Q8N5Z0; -.
DR   OpenTargets; ENSG00000109576; -.
DR   PharmGKB; PA24364; -.
DR   eggNOG; KOG0634; Eukaryota.
DR   eggNOG; COG1167; LUCA.
DR   GeneTree; ENSGT00390000004594; -.
DR   HOGENOM; HOG000223057; -.
DR   HOVERGEN; HBG050429; -.
DR   InParanoid; Q8N5Z0; -.
DR   KO; K00825; -.
DR   OMA; QQWGEKG; -.
DR   OrthoDB; EOG091G0B8J; -.
DR   PhylomeDB; Q8N5Z0; -.
DR   TreeFam; TF328598; -.
DR   BioCyc; MetaCyc:HS03239-MONOMER; -.
DR   BRENDA; 2.6.1.39; 2681.
DR   BRENDA; 2.6.1.7; 2681.
DR   Reactome; R-HSA-71064; Lysine catabolism.
DR   Reactome; R-HSA-71240; Tryptophan catabolism.
DR   SABIO-RK; Q8N5Z0; -.
DR   UniPathway; UPA00868; UER00838.
DR   ChiTaRS; AADAT; human.
DR   EvolutionaryTrace; Q8N5Z0; -.
DR   GenomeRNAi; 51166; -.
DR   PRO; PR:Q8N5Z0; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   Bgee; ENSG00000109576; -.
DR   CleanEx; HS_AADAT; -.
DR   ExpressionAtlas; Q8N5Z0; baseline and differential.
DR   Genevisible; Q8N5Z0; HS.
DR   GO; GO:0005759; C:mitochondrial matrix; TAS:Reactome.
DR   GO; GO:0047536; F:2-aminoadipate transaminase activity; IDA:UniProtKB.
DR   GO; GO:0016212; F:kynurenine-oxoglutarate transaminase activity; IDA:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IPI:UniProtKB.
DR   GO; GO:0030170; F:pyridoxal phosphate binding; IEA:Ensembl.
DR   GO; GO:0006103; P:2-oxoglutarate metabolic process; IDA:UniProtKB.
DR   GO; GO:0009058; P:biosynthetic process; IEA:InterPro.
DR   GO; GO:0006536; P:glutamate metabolic process; IDA:UniProtKB.
DR   GO; GO:0070189; P:kynurenine metabolic process; IDA:UniProtKB.
DR   GO; GO:0033512; P:L-lysine catabolic process to acetyl-CoA via saccharopine; IEA:UniProtKB-UniPathway.
DR   GO; GO:0006554; P:lysine catabolic process; TAS:Reactome.
DR   GO; GO:0006569; P:tryptophan catabolic process; TAS:Reactome.
DR   GO; GO:0019441; P:tryptophan catabolic process to kynurenine; IEA:Ensembl.
DR   Gene3D; 3.40.640.10; -; 1.
DR   Gene3D; 3.90.1150.10; -; 1.
DR   InterPro; IPR004839; Aminotransferase_I/II.
DR   InterPro; IPR015424; PyrdxlP-dep_Trfase.
DR   InterPro; IPR015421; PyrdxlP-dep_Trfase_major_sub1.
DR   InterPro; IPR015422; PyrdxlP-dep_Trfase_sub2.
DR   Pfam; PF00155; Aminotran_1_2; 1.
DR   SUPFAM; SSF53383; SSF53383; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Aminotransferase;
KW   Complete proteome; Mitochondrion; Polymorphism; Pyridoxal phosphate;
KW   Reference proteome; Transferase; Transit peptide.
FT   TRANSIT       1     29       Mitochondrion. {ECO:0000255}.
FT   CHAIN        30    425       Kynurenine/alpha-aminoadipate
FT                                aminotransferase, mitochondrial.
FT                                /FTId=PRO_0000020602.
FT   BINDING      20     20       Substrate.
FT   BINDING      74     74       Substrate.
FT   BINDING     142    142       Substrate.
FT   BINDING     202    202       Substrate.
FT   BINDING     399    399       Substrate.
FT   MOD_RES      69     69       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:Q9WVM8}.
FT   MOD_RES     179    179       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:Q9WVM8}.
FT   MOD_RES     263    263       N6-(pyridoxal phosphate)lysine;
FT                                alternate.
FT   MOD_RES     263    263       N6-acetyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:Q9WVM8}.
FT   MOD_RES     263    263       N6-succinyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:Q9WVM8}.
FT   MOD_RES     339    339       N6-acetyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:Q9WVM8}.
FT   MOD_RES     339    339       N6-succinyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:Q9WVM8}.
FT   MOD_RES     367    367       N6-acetyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:Q9WVM8}.
FT   MOD_RES     367    367       N6-succinyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:Q9WVM8}.
FT   MOD_RES     422    422       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:Q9WVM8}.
FT   VAR_SEQ      23     23       T -> SEKRA (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_009874.
FT   VARIANT     243    243       V -> I (in dbSNP:rs56350236).
FT                                /FTId=VAR_061005.
FT   CONFLICT    103    103       P -> Q (in Ref. 4; AAH31068).
FT                                {ECO:0000305}.
FT   CONFLICT    380    380       L -> S (in Ref. 3; BAG51596).
FT                                {ECO:0000305}.
FT   HELIX         3      6       {ECO:0000244|PDB:5TF5}.
FT   HELIX         9     13       {ECO:0000244|PDB:5TF5}.
FT   HELIX        19     21       {ECO:0000244|PDB:2R2N}.
FT   STRAND       23     25       {ECO:0000244|PDB:5TF5}.
FT   TURN         26     28       {ECO:0000244|PDB:5TF5}.
FT   HELIX        43     45       {ECO:0000244|PDB:5TF5}.
FT   STRAND       47     55       {ECO:0000244|PDB:5TF5}.
FT   TURN         56     58       {ECO:0000244|PDB:4GEB}.
FT   STRAND       61     63       {ECO:0000244|PDB:5TF5}.
FT   HELIX        65     71       {ECO:0000244|PDB:5TF5}.
FT   HELIX        81     95       {ECO:0000244|PDB:5TF5}.
FT   TURN         98    101       {ECO:0000244|PDB:5TF5}.
FT   HELIX       104    106       {ECO:0000244|PDB:5TF5}.
FT   STRAND      109    116       {ECO:0000244|PDB:5TF5}.
FT   HELIX       117    128       {ECO:0000244|PDB:5TF5}.
FT   STRAND      134    137       {ECO:0000244|PDB:5TF5}.
FT   HELIX       143    149       {ECO:0000244|PDB:5TF5}.
FT   HELIX       150    152       {ECO:0000244|PDB:5TF5}.
FT   STRAND      155    158       {ECO:0000244|PDB:5TF5}.
FT   HELIX       168    175       {ECO:0000244|PDB:5TF5}.
FT   HELIX       180    184       {ECO:0000244|PDB:5TF5}.
FT   HELIX       186    188       {ECO:0000244|PDB:5TF5}.
FT   STRAND      192    196       {ECO:0000244|PDB:5TF5}.
FT   TURN        202    204       {ECO:0000244|PDB:5TF5}.
FT   HELIX       210    222       {ECO:0000244|PDB:5TF5}.
FT   STRAND      226    230       {ECO:0000244|PDB:5TF5}.
FT   HELIX       234    236       {ECO:0000244|PDB:5TF5}.
FT   STRAND      239    241       {ECO:0000244|PDB:5TF5}.
FT   HELIX       247    249       {ECO:0000244|PDB:5TF5}.
FT   STRAND      251    253       {ECO:0000244|PDB:5TF5}.
FT   STRAND      255    260       {ECO:0000244|PDB:5TF5}.
FT   TURN        262    265       {ECO:0000244|PDB:5EUN}.
FT   TURN        267    270       {ECO:0000244|PDB:4GE9}.
FT   STRAND      272    277       {ECO:0000244|PDB:5TF5}.
FT   HELIX       278    289       {ECO:0000244|PDB:5TF5}.
FT   TURN        290    292       {ECO:0000244|PDB:5TF5}.
FT   STRAND      293    295       {ECO:0000244|PDB:4GE7}.
FT   HELIX       297    340       {ECO:0000244|PDB:5TF5}.
FT   STRAND      342    347       {ECO:0000244|PDB:5TF5}.
FT   STRAND      351    360       {ECO:0000244|PDB:5TF5}.
FT   HELIX       367    371       {ECO:0000244|PDB:5TF5}.
FT   HELIX       373    376       {ECO:0000244|PDB:5TF5}.
FT   STRAND      381    383       {ECO:0000244|PDB:4GDY}.
FT   HELIX       384    387       {ECO:0000244|PDB:5TF5}.
FT   STRAND      388    390       {ECO:0000244|PDB:5TF5}.
FT   STRAND      391    393       {ECO:0000244|PDB:3UE8}.
FT   STRAND      397    401       {ECO:0000244|PDB:5TF5}.
FT   TURN        402    404       {ECO:0000244|PDB:3UE8}.
FT   HELIX       407    423       {ECO:0000244|PDB:5TF5}.
SQ   SEQUENCE   425 AA;  47352 MW;  448CCAAB2173A7BA CRC64;
     MNYARFITAA SAARNPSPIR TMTDILSRGP KSMISLAGGL PNPNMFPFKT AVITVENGKT
     IQFGEEMMKR ALQYSPSAGI PELLSWLKQL QIKLHNPPTI HYPPSQGQMD LCVTSGSQQG
     LCKVFEMIIN PGDNVLLDEP AYSGTLQSLH PLGCNIINVA SDESGIVPDS LRDILSRWKP
     EDAKNPQKNT PKFLYTVPNG NNPTGNSLTS ERKKEIYELA RKYDFLIIED DPYYFLQFNK
     FRVPTFLSMD VDGRVIRADS FSKIISSGLR IGFLTGPKPL IERVILHIQV STLHPSTFNQ
     LMISQLLHEW GEEGFMAHVD RVIDFYSNQK DAILAAADKW LTGLAEWHVP AAGMFLWIKV
     KGINDVKELI EEKAVKMGVL MLPGNAFYVD SSAPSPYLRA SFSSASPEQM DVAFQVLAQL
     IKESL
//
